Dragonfly Therapeutics, Inc. Announces Clinical Collaboration to Evaluate DF9001, an EGFR targeting TriNKET®, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors

DF9001 is currently being evaluated as a monotherapy for the treatment of Non-Small Cell Lung Cancer, Renal Cell Carcinoma and Head and Neck Squamous Cell Carcinoma. The clinical trial collaboration

Related Keywords

Canada ,United States ,America ,Annee Deconinck , ,Merck Co Inc ,Merck Sharp Dohme ,Prnewswire Dragonfly Therapeutics Inc ,Bristol Myers Squibb ,Non Small Cell Lung Cancer ,Renal Cell Carcinoma ,Neck Squamous Cell ,Bill Haney ,North America ,Merck Sharp ,Ihr Portfolio ,